Risk factors for multiple myeloma: A hospital-based case-control study in Northwest China

Cancer Epidemiology

Volumn 36, Issue 5, 2012, Pages 439-444

  Wang, Qixia ^a   Wang, Yiwei ^a   Ji, Zhaohua ^b   Chen, Xiequn ^a   Pan, Yaozhu ^a   Gao, Guangxun ^a   Gu, Hongtao ^a   Yang, Yang ^a   Choi, Bernard C K ^c   Yan, Yongping ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Case control study; Multiple myeloma; Northwest China; Risk factor

Indexed keywords

ADULT; ARTICLE; CHINA; CONTROLLED STUDY; FEMALE; FOOD INTAKE; FOOD PRESERVATION; GARLIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SHALLOT; SOYBEAN; TEA;

CASE-CONTROL STUDIES; CAUSALITY; CHINA; CONFIDENCE INTERVALS; ENVIRONMENTAL EXPOSURE; FAMILY HEALTH; FEMALE; FOOD HABITS; FOOD PRESERVATION; GARLIC; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RISK FACTORS; RISK REDUCTION BEHAVIOR; SOY FOODS; TEA;

EID: 84865865684     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.05.002     Document Type: Article

References (47)

1. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341(21):1565-1571.
2. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed refractory myeloma. N Engl J Med 2003, 348(26):2609-2617.
3. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352(24):2487-2498.
4. Rajkumar S.V., Hayman S.R., Lacy M.Q., Dispenzieri A., Geyer S.M., Kabat B., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005, 106(13):4050-4053.
5. Richardson P.G., Blood E., Mitsiades C.S., Jagannath S., Zeldenrust S.R., Alsina M., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006, 108(10):3458-3464.
6. Morgan G.J., Davies F.E., Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother 2002, 56(5):223-234.
7. Ferlay J., Shin H.R., Bray F., Parkin D.M. GLOBOCAN 2008 v1. 2, cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet] 2010, International Agency for Research on Cancer, Lyon, France, Available from: http://globocan.iarc.fr [accessed on 01.12.11].
8. Jain R., Mills P., Parikh-Patel A. Cancer incidence in the south Asian population of California, 1988-2000. J Carcinogen 2005, 4(1):21.
9. Chan V., Song K., Mang O., Ip D.K., Au W.Y. Lower incidence of plasma cell neoplasm is maintained in migrant Chinese to British Columbia: findings from a 30-year survey. Leuk Lymphoma 2011, 52(12):2316-2320.
10. Chang E.T., Canchola A.J., Clarke C.A., Lu Y., West D.W., Bernstein L., et al. Dietary phytocompounds and risk of lymphoid malignancies in the California Teachers Study cohort. Cancer Causes Control 2011, 22(2):237-249.
11. Brown L.M., Gridley G., Pottern L.M., Baris D., Swanso C.A., Silverman D.T., et al. Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control 2001, 12(2):117-125.
12. Fritschi L., Ambrosini G.L., Kliewer E.V., Johnson K.C. Dietary fish intake and risk of leukaemia, multiple myeloma, and non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2004, 13(4):532-537.
13. Hemminki K., Li X., Czene K. Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer 2004, 108(1):109-114.
14. Goldin L.R., Pfeiffer R.M., Gridley G., Gail M.H., Li X., Mellemkjaer L., et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer 2004, 100(9):1902-1908.
15. Lynch H.T., Ferrara K., Barlogie B., Coleman E.A., Lynch J.F., Weisenburger D., et al. Familial myeloma. N Engl J Med 2008, 359(2):152-157.
16. Ogmundsdottir H.M., Haraldsdottirm V., Johannesson G.M., Olafsdottir G., Bjarnadottir K., Sigvaldason H., et al. Familiality of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families. Haematologica 2005, 90(1):66-71.
17. Landgren O., Kristinsson S.Y., Goldin L.R., Caporaso N.E., Blimark C., Mellqvist U.H., et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 2009, 114(4):791-795.
18. Chan J.M., Oh W.K., Xie W., Regan M.M., Stampfer M.J., King I.B., et al. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol 2009, 27(22):3577.
19. Lai J.S., Cook K., Stone A., Beaumont J., Cella D. Classical test theory and item response theory/Rasch model to assess differences between patient-reported fatigue using 7-day and 4-week recall periods. J Clin Epidemiol 2009, 62(9):991-997.
20. Hashibe M., Mathew B., Kuruvilla B., Thomas G., Sankaranarayanan R., Parkin D.M., et al. Chewing tobacco, alcohol, and the risk of erythroplakia. Cancer Epidemiol Biomark Prev 2000, 9(7):639.
21. Zou G.Y. On the estimation of additive interaction by use of the four-by-two table and beyond. Am J Epidemiol 2008, 168(2):212.
22. Landgren O., Linet M.S., McMaster M.L., Gridley G., Hemminki K., Goldin L.R. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006, 118(12):3095-3098.
23. Ghosh S., McLaughlin J.R., Spinelli J.J., Dosman J.A., McDuffie H.H., Pahwa P. Multiple myeloma and occupational exposures: a population-based case-control study. J Occup Environ Med 2011, 53(6):641-646.
24. Fleischauer A.T., Arab L. Garlic and cancer: a critical review of the epidemiologic literature. J Nutr 2001, 131(3s):1032S-1040S.
25. Kim J.Y., Kwon O. Garlic intake and cancer risk: an analysis using the Food and Drug Administration's evidence-based review system for the scientific evaluation of health claims. Am J Clin Nutr 2009, 89(1):257-264.
26. Arnault I., Auger J. Seleno-compounds in garlic and onion. J Chromatogr A 2006, 1112(1-2):23-30.
27. Dong Y., Lisk D., Block E., Ip C. Characterization of the biological activity of gamma-glutamyl-Se-methylselenocysteine: a novel, naturally occurring anticancer agent from garlic. Cancer Res 2001, 61(7):2923-2928.
28. Cornwell T., Cohick W., Raskin I. Dietary phytoestrogens and health. Phytochemistry 2004, 65(8):995-1016.
29. Chihara D., Matsuo K., Kanda J., Hosono S., Ito H., Nakamura S., et al. Inverse association between soy intake and non-Hodgkin lymphoma risk among women: a case-control study in Japan. Ann Oncol 2011, July 15 [Epub ahead of print].
30. Andres S., Abraham K., Appel K.E., Lampen A. Risks and benefits of dietary isoflavones for cancer. Crit Rev Toxicol 2011, 41(6):463-506.
31. McCall J.L., Burich R.A., Mack P.C. GCP, a genistein-rich compound, inhibits proliferation and induces apoptosis in lymphoma cell lines. Leuk Res 2010, 34(1):69-76.
32. Sarkar F.H., Li Y. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev 2002, 21(3-4):265-280.
33. Gilmore T.D. Multiple myeloma: lusting for NF-kappaB. Cancer Cell 2007, 12(2):95-97.
34. Harvey R.D., Lonial S. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol 2007, 3(6):639-647.
35. Brown M.D. Green tea (Camellia sinensis) extract and its possible role in the prevention of cancer. Altern Med Rev 1999, 4(5):360-370.
36. Binns C.W., Lee A.H., Fraser M.L. Tea or coffee? A case study on evidence for dietary advice. Public Health Nutr 2008, 11(11):1132-1141.
37. Cabrera C., Artacho R., Gimenez R. Beneficial effects of green tea-a review. J Am Coll Nutr 2006, 25(2):79-99.
38. Shammas M.A., Neri P., Koley H., Batchu R.B., Bertheau R.C., Munshi V., et al. Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 2006, 108(8):2804-2810.
39. Nakazato T., Ito K., Ikeda Y., Kizaki M. Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clin Cancer Res 2005, 11(16):6040-6049.
40. Hosgood H.D., Baris D., Zahm S.H., Zheng T., Cross A.J. Diet and risk of multiple myeloma in Connecticut women. Cancer Causes Control 2007, 18(10):1065-1076.
41. Yu H., Hwang J.Y., Ro J., Kim J., Chang N. Vegetables, but not pickled vegetables, are negatively associated with the risk of breast cancer. Nutr Cancer 2010, 62(4):443-453.
42. Tsugane S., Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 2007, 10(2):75-83.
43. Jian L., Zhang D.H., Lee A.H., Binns C.W. Do preserved foods increase prostate cancer risk?. Br J Cancer 2004, 90(9):1792-1795.
44. Matsubara S., Takasu S., Tsukamoto T., Mutoh M., Masuda S., Sugimura T., et al. Induction of glandular stomach cancers in Helicobacter pylori-infected Mongolian gerbils by 1-nitrosoindole-3-acetonitrile. Int J Cancer 2012, 130(2):259-266.
45. Yuan Z., Ding Y. Mutagenesis and anti-mutagenicity in several traditional Zhejiang preserved foods. Carcinogenesis Teratogenesis Mutagenesis 2003, 15:91-93.
46. Lee C.H., Cragoe E.J., Edwards A.M. Control of hepatocyte DNA synthesis by intracellular pH and its role in the action of tumor promoters. J Cell Physiol 2003, 195(1):61-69.
47. Riboli E., Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr 2003, 78(3 Suppl):559S-569S.